Agios Net Debt from 2010 to 2026
| AGIO Stock | USD 28.16 0.72 2.62% |
Net Debt | First Reported 2012-12-31 | Previous Quarter -32.1 M | Current Value -48.2 M | Quarterly Volatility 330.3 M |
Check Agios Pharm financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Agios Pharm's main balance sheet or income statement drivers, such as Depreciation And Amortization of 8 M, Interest Expense of 15.4 M or Selling General Administrative of 189.3 M, as well as many indicators such as Price To Sales Ratio of 34.59, Dividend Yield of 0.0 or PTB Ratio of 1.32. Agios financial statements analysis is a perfect complement when working with Agios Pharm Valuation or Volatility modules.
Agios | Net Debt | Build AI portfolio with Agios Stock |
Evaluating Agios Pharm's Net Debt across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Agios Pharm's fundamental strength.
Latest Agios Pharm's Net Debt Growth Pattern
Below is the plot of the Net Debt of Agios Pharm over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Agios Pharm's Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Agios Pharm's overall financial position and show how it may be relating to other accounts over time.
| Net Debt | 10 Years Trend |
|
Net Debt |
| Timeline |
Agios Net Debt Regression Statistics
| Arithmetic Mean | (174,403,594) | |
| Geometric Mean | 75,449,953 | |
| Coefficient Of Variation | (142.12) | |
| Mean Deviation | 191,179,721 | |
| Median | (71,560,000) | |
| Standard Deviation | 247,857,059 | |
| Sample Variance | 61433.1T | |
| Range | 838.2M | |
| R-Value | 0.22 | |
| Mean Square Error | 62238.5T | |
| R-Squared | 0.05 | |
| Significance | 0.39 | |
| Slope | 10,998,297 | |
| Total Sum of Squares | 982929.9T |
Agios Net Debt History
Other Fundumenentals of Agios Pharm
Agios Pharm Net Debt component correlations
Click cells to compare fundamentals
About Agios Pharm Financial Statements
Agios Pharm investors utilize fundamental indicators, such as Net Debt, to predict how Agios Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Debt | -22.1 M | -23.3 M | |
| Net Debt To EBITDA | 0.05 | 0.05 |
Pair Trading with Agios Pharm
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Agios Pharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agios Pharm will appreciate offsetting losses from the drop in the long position's value.Moving against Agios Stock
| 0.71 | ENTA | Enanta Pharmaceuticals Earnings Call This Week | PairCorr |
| 0.68 | GMAB | Genmab AS | PairCorr |
| 0.67 | ACW | Actinogen Medical | PairCorr |
| 0.47 | OBIO | Orchestra BioMed Holdings Upward Rally | PairCorr |
| 0.45 | FHTX | Foghorn Therapeutics | PairCorr |
The ability to find closely correlated positions to Agios Pharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Agios Pharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Agios Pharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Agios Pharm to buy it.
The correlation of Agios Pharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Agios Pharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Agios Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Agios Pharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Agios Pharm Correlation against competitors. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Will Biotechnology sector continue expanding? Could Agios diversify its offerings? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Agios Pharm data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (7.01) | Revenue Per Share | Quarterly Revenue Growth 0.437 | Return On Assets | Return On Equity |
Agios Pharm's market price often diverges from its book value, the accounting figure shown on Agios's balance sheet. Smart investors calculate Agios Pharm's intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Agios Pharm's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Agios Pharm's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Agios Pharm represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.